599 related articles for article (PubMed ID: 33528830)
21. Solid lipid nanoparticles for enhanced oral absorption: A review.
Salah E; Abouelfetouh MM; Pan Y; Chen D; Xie S
Colloids Surf B Biointerfaces; 2020 Dec; 196():111305. PubMed ID: 32795844
[TBL] [Abstract][Full Text] [Related]
22. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances.
Shreya AB; Raut SY; Managuli RS; Udupa N; Mutalik S
AAPS PharmSciTech; 2018 Dec; 20(1):15. PubMed ID: 30564942
[TBL] [Abstract][Full Text] [Related]
23. Lipid-based nanocarriers for enhanced delivery of plant-derived bioactive molecules: a comprehensive review.
Kothapalli P; Vasanthan M
Ther Deliv; 2024 Feb; 15(2):135-155. PubMed ID: 38214118
[TBL] [Abstract][Full Text] [Related]
24. Development of Lipid-Based Nanocarriers for Increasing Gastrointestinal Absorption of Lupinifolin.
Musika J; Chudapongse N
Planta Med; 2020 Mar; 86(5):364-372. PubMed ID: 32005042
[TBL] [Abstract][Full Text] [Related]
25. Progress and prospects of polysaccharide-based nanocarriers for oral delivery of proteins/peptides.
Yuan H; Guo C; Liu L; Zhao L; Zhang Y; Yin T; He H; Gou J; Pan B; Tang X
Carbohydr Polym; 2023 Jul; 312():120838. PubMed ID: 37059563
[TBL] [Abstract][Full Text] [Related]
26. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
[TBL] [Abstract][Full Text] [Related]
27. Lipid-Based Nanosystem As Intelligent Carriers for Versatile Drug Delivery Applications.
Harshita ; Barkat MA; Das SS; Pottoo FH; Beg S; Rahman Z
Curr Pharm Des; 2020; 26(11):1167-1180. PubMed ID: 32026769
[TBL] [Abstract][Full Text] [Related]
28. Toxicity evaluation of nanocarriers for the oral delivery of macromolecular drugs.
Ojer P; Iglesias T; Azqueta A; Irache JM; López de Cerain A
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):206-17. PubMed ID: 26493712
[TBL] [Abstract][Full Text] [Related]
29. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment.
Wong CY; Al-Salami H; Dass CR
J Control Release; 2017 Oct; 264():247-275. PubMed ID: 28887133
[TBL] [Abstract][Full Text] [Related]
30. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Patel RJ; Ajazuddin ; Ravichandiran V; Murty US; Alexander A
J Control Release; 2020 May; 321():372-415. PubMed ID: 32061621
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers.
Florek J; Caillard R; Kleitz F
Nanoscale; 2017 Oct; 9(40):15252-15277. PubMed ID: 28984885
[TBL] [Abstract][Full Text] [Related]
32. Nanocarriers for oral drug delivery.
Zhang L; Wang S; Zhang M; Sun J
J Drug Target; 2013 Jul; 21(6):515-27. PubMed ID: 23621127
[TBL] [Abstract][Full Text] [Related]
33. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
34. Polymeric Biomaterial and Lipid Based Nanoparticles for Oral Drug Delivery.
Dilnawaz F
Curr Med Chem; 2017; 24(22):2423-2438. PubMed ID: 27804879
[TBL] [Abstract][Full Text] [Related]
35. Solid lipid nanocarriers in drug delivery: characterization and design.
Mu H; Holm R
Expert Opin Drug Deliv; 2018 Aug; 15(8):771-785. PubMed ID: 30064267
[TBL] [Abstract][Full Text] [Related]
36. Cancer chemotherapy with lipid-based nanocarriers.
Liu D; Zhang N
Crit Rev Ther Drug Carrier Syst; 2010; 27(5):371-417. PubMed ID: 21083528
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers.
Lin CH; Chen CH; Lin ZC; Fang JY
J Food Drug Anal; 2017 Apr; 25(2):219-234. PubMed ID: 28911663
[TBL] [Abstract][Full Text] [Related]
38. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
Roger E; Lagarce F; Garcion E; Benoit JP
Nanomedicine (Lond); 2010 Feb; 5(2):287-306. PubMed ID: 20148639
[TBL] [Abstract][Full Text] [Related]
39. Self-Assembling Drug Formulations with Tunable Permeability and Biodegradability.
Gaynanova G; Vasileva L; Kashapov R; Kuznetsova D; Kushnazarova R; Tyryshkina A; Vasilieva E; Petrov K; Zakharova L; Sinyashin O
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833877
[TBL] [Abstract][Full Text] [Related]
40. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
